STOCK TITAN
  1. Home
  2. News
  3. ARQT

Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company based in Westlake Village, California, specializing in developing and commercializing treatments for dermatological diseases. Founded in 2016, Arcutis leverages recent advances in immunology and inflammation to create differentiated therapies targeting immune-mediated dermatological conditions.

Arcutis' lead product, ZORYVE (roflumilast) cream, is a topical treatment for plaque psoriasis and atopic dermatitis. The company has recently launched ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis. Both formulations utilize roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor that has shown significant improvement in clinical trials.

Arcutis is also advancing its pipeline with ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema, and ARQ-255 for alopecia areata. The company champions meaningful innovation to address the urgent needs of patients living with chronic, immune-mediated skin conditions, aiming to improve treatment options and patient outcomes.

In recent developments, Arcutis has been actively participating in industry conferences, securing strategic collaborations, and expanding its workforce. The company's financial health is robust, with a strong cash position bolstered by a recent public offering and a strategic licensing agreement in Japan. Arcutis continues to focus on long-term growth and innovation, with multiple ongoing clinical programs targeting various inflammatory dermatological conditions.

For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

News

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announces a quarterly investor conference call and webcast on February 27, 2024, to report fourth-quarter and full-year financial results and provide a business update. The company focuses on immuno-dermatology innovations, with FDA-approved products and a robust pipeline for inflammatory dermatological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.69%
Tags
conferences earnings
-
News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) granted 33,750 restricted stock units to five new employees under the 2022 Inducement Plan. The units vest over four years, with 25% vesting annually, subject to continuous employment. The grant date was February 1, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
-
News

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference on February 7, 2024, at 10:00 am ET. The company's management will engage in a fireside chat, with the webcast accessible on the company's website. A replay will be available for 180 days after the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. announces the approval of ZORYVE foam, a novel steroid-free topical treatment for seborrheic dermatitis, by the FDA. The Journal of American Academy of Dermatology published positive results from the Phase 3 STRATUM trial, showing 80% of individuals achieving treatment success and 51% reaching complete clearance at Week 8. The study demonstrates significant improvements in itch, scaling, and redness, with ZORYVE foam showing a favorable safety and tolerability profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.34%
Tags
clinical trial
-
News

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the launch of ZORYVE (roflumilast) topical foam, 0.3%, in the United States for the treatment of seborrheic dermatitis in individuals 9 years of age and older. ZORYVE is a steroid-free foam with a new mechanism of action, providing rapid disease clearance and significant reduction in itch. The drug is available in pharmacies with strong reimbursement from major pharmacy benefit managers. Clinical trials showed that more than half of the subjects achieved complete clearance, and 3 in 4 patients achieved treatment success at 8 weeks, with over 40% achieving success as early as two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
none
-
News

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. announced new data from the STRATUM study, showing that ZORYVE foam was 3.5 times more likely to achieve IGA Success in patients with seborrheic dermatitis who had an inadequate response, contraindication, or intolerance to steroids. The foam also significantly improved quality of life scores, with minimal side effects. The study was presented at the 2024 Winter Clinical Dermatology Conference in Hawaii.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced new patient response data for roflumilast cream 0.15% at the 2024 Winter Clinical Dermatology Conference. The data showed that 91.5% of individuals treated with the cream had a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks. The cream demonstrated statistically significant improvement in EASI scores compared to the vehicle. Dr. Lawrence Eichenfield and Dr. Patrick Burnett provided positive comments on the efficacy and reliability of roflumilast cream for atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Rhea-AI Summary
Arcutis Biotherapeutics, ticker symbol ARQT, has received FDA approval for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older. ZORYVE foam provides rapid disease clearance and significant reduction in itch, with nearly 80% of individuals achieving the primary efficacy endpoint of IGA Success and just over 50% of individuals reaching complete clearance at Week 8 in the STRATUM trial. This is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades. Seborrheic dermatitis affects more than 10 million people in the United States, and the commercial product is expected to be available by the end of January. Arcutis Biotherapeutics will host a conference call on Monday, December 18 at 8:30 a.m. EST to discuss the approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
fda approval
-
News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) granted 90,500 restricted stock units and 106,500 stock options to 7 newly hired employees under the 2022 Inducement Plan. The restricted stock units and options vest over four years, subject to continuous employment. The stock options have a ten-year term and an exercise price of $1.99 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.56%
Tags
none
News

FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announced that the FDA has accepted its supplemental new drug application for roflumilast cream 0.15% for the treatment of atopic dermatitis in adults and children down to age 6. The FDA has set a PDUFA target action date of July 07, 2024. Roflumilast cream is a once-daily, steroid-free, phosphodiesterase-4 (PDE4) inhibitor. The sNDA is supported by positive efficacy and safety data from the pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials. The company aims to provide a new topical option for the millions of Americans living with atopic dermatitis, potentially becoming the new standard of care in the treatment of the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.86%
Tags
clinical trial

FAQ

What is the current stock price of Arcutis Biotherapeutics (ARQT)?

The current stock price of Arcutis Biotherapeutics (ARQT) is $14.99 as of December 20, 2024.

What is the market cap of Arcutis Biotherapeutics (ARQT)?

The market cap of Arcutis Biotherapeutics (ARQT) is approximately 1.8B.

What does Arcutis Biotherapeutics, Inc. specialize in?

Arcutis specializes in developing and commercializing treatments for dermatological diseases, focusing on immune-mediated conditions.

What are the main products of Arcutis Biotherapeutics?

Arcutis' main products include ZORYVE (roflumilast) cream for plaque psoriasis and atopic dermatitis, and ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis.

Where is Arcutis Biotherapeutics headquartered?

Arcutis Biotherapeutics is headquartered in Westlake Village, California.

When was Arcutis Biotherapeutics founded?

Arcutis Biotherapeutics was founded in 2016.

What is ZORYVE?

ZORYVE is a brand name for Arcutis' roflumilast cream and topical foam, used to treat plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

What is the mechanism of action for ZORYVE?

ZORYVE utilizes roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor, which helps reduce inflammation by regulating immune response mediators.

What are Arcutis' latest achievements?

Recent achievements include the successful launch of ZORYVE foam, strategic licensing agreements, and strong financial results from a public offering.

How is Arcutis ensuring long-term growth?

Arcutis ensures long-term growth through continuous innovation, expanding clinical programs, strategic collaborations, and robust financial management.

What are some of Arcutis' ongoing projects?

Ongoing projects include clinical programs for ARQ-252 for hand eczema, ARQ-255 for alopecia areata, and additional studies for topical roflumilast formulations.

Where can I get more information about Arcutis Biotherapeutics?

For more information, visit Arcutis' official website at www.arcutis.com or follow them on LinkedIn, Facebook, Instagram, and X.

Stock ARQT logo
Arcutis Biotherapeutics, Inc.

Nasdaq:ARQT

ARQT Rankings

#2039 Ranked by Market Cap
N/A Ranked by Dividends

ARQT Stock Data

1.80B
103.96M
2.15%
113.6%
21.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WESTLAKE VILLAGE